Newbies - Buying interest ahead of NVAX at The World Vaccine Congress in DC Tuesday
Novavax is looking to make a big splash and is featured Tuesday afternoon in a discussion on RSV in conjunction with the National Institute of Health. They will also be featured throughout the conference on VLP vaccines for Influenza. Last, with the H7N9 epidemic in China, Novavax should receive additional attention during discussion on Pandemic vaccines because of their existing contract with BARDA.
They are also up for an award for Best Early-Stage Vaccine. The award presentations are Wednesday evening after the conference.
Best Early-Stage Vaccine Biotech Final Shortlist:
To verify all the details, just google World Vaccine Congress to see the Conference website. It kicks off Tuesday morning at 8am. Should be an existing week.
and though a ways off... very exciting is the October PATH RSV conference... where Dr. Glenn represents the Novavax RSV vaccine. PATH is determined to conquer this disease ... I do expect them to extend the current funding with Novavax for more phase II trials. We may well hear on this quite soon.
The RSV phase 2 study results released a week ago are driving much of the interest, especially among the hedge funds. In the conference call on Phase 2 results, the company noted that they were saving additional data for the World Vaccine Conference which is tomorrow evening. I believe they are scheduled for 5pm. I'm excited to see what new data is released! Could bring us some excellent press coverage this week. GLTA